Lifesci Capital Initiates Coverage on Oruka Therapeutics (NASDAQ:ORKA)

Investment analysts at Lifesci Capital initiated coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a report released on Monday, Benzinga reports. The brokerage set an “outperform” rating and a $41.00 price target on the stock. Lifesci Capital’s price target would suggest a potential upside of 61.04% from the stock’s current price.

ORKA has been the topic of several other reports. Wedbush started coverage on Oruka Therapeutics in a report on Wednesday, September 4th. They set an “outperform” rating and a $40.00 target price on the stock. Jefferies Financial Group initiated coverage on Oruka Therapeutics in a report on Friday. They issued a “buy” rating and a $40.00 target price for the company. Finally, TD Cowen assumed coverage on Oruka Therapeutics in a report on Monday. They set a “buy” rating on the stock.

Oruka Therapeutics Stock Performance

ORKA traded up $0.57 on Monday, reaching $25.46. 7,779 shares of the company’s stock were exchanged, compared to its average volume of 49,485. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.